# Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma

> **NCT02077114** · PHASE1 · COMPLETED · sponsor: **Herlev Hospital** · enrollment: 10 (actual)

## Conditions studied

- Malignant Melanoma With Metastasis

## Interventions

- **BIOLOGICAL:** Vaccine consisting of a peptide derived from the protein IDO

## Key facts

- **NCT ID:** NCT02077114
- **Lead sponsor:** Herlev Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-09
- **Final completion:** —
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2014-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02077114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02077114, "Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02077114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*